Aethlon Medical to Host Third Quarter Financial Results Call
Aethlon Medical, Inc. (Nasdaq: AEMD), a pioneering medical therapeutic company, is set to announce its fiscal third quarter financial results. This event is scheduled to take place soon, emphasizing the company's progress in developing therapies for cancer and severe infectious diseases.
Event Details and Participation
The financial results will be released at 4:15 p.m. ET on a day not specified. Following this, management will lead a conference call at 4:30 p.m. ET to delve into the results and discuss significant corporate updates. After the formal presentation, a question and answer session will allow participants to engage with the management team.
How to Participate
All interested individuals can register for the conference call via Aethlon Medical's website. Upon registration, participants will receive the necessary dial-in details. For those who may not have internet access, a toll-free number is available, along with an international dial-in option. This ensures everyone can join in on the important discussions.
Replaying the Conference Call
A replay of this conference call will be accessible approximately one hour after its conclusion. It will remain available until a specified date. Callers can access the replay using provided dial-in numbers, allowing those who may have missed the live call to catch up on the critical information shared.
About Aethlon Medical and the Hemopurifier
Aethlon Medical is dedicated to developing innovative solutions such as the Hemopurifier, a clinical stage immunotherapeutic device aimed at addressing cancer and life-threatening viral infections. This innovative device works by removing dangerous viruses and harmful exosomes from biological fluids. In clinical studies, the Hemopurifier has demonstrated effectiveness, particularly in oncology, where it potentially counters immune suppression and ease metastasis.
FDA Designations and Opportunities
The Hemopurifier has received FDA designation as a Breakthrough Device. This classification is crucial for patients with advanced cancer who may not be respond to typical treatments. Furthermore, an Investigational Device Exemption (IDE) application has been submitted regarding its efficacy against dangerous viruses that lack approved therapies.
Exploring Further Information
Further details about Aethlon Medical and its pioneering device can be found on their website. This online resource offers insights into ongoing research and how the Hemopurifier is setting new standards in the treatment of severe medical conditions.
Frequently Asked Questions
1. What is the main focus of Aethlon Medical?
Aethlon Medical specializes in developing therapeutics focused on treating cancer and severe infectious diseases.
2. What is the Hemopurifier?
The Hemopurifier is a clinical stage device designed to remove life-threatening viruses and harmful exosomes from the body, highlighting its role in cancer therapy and immunotherapy.
3. When will Aethlon Medical's Q3 financial results be available?
Although the specific date is not provided, the results are expected to be released alongside the conference call.
4>How can participants join the Aethlon Medical conference call?
Interested individuals can register on Aethlon Medical's website to receive the dial-in information for the conference call.
5. How long will the replay of the conference call be available?
The replay of the call will be accessible roughly one hour after it ends, remaining available for a limited period.
